DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of ...

Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use insulin.

In May 2026, Dexcom disclosed FDA-enforced, Class II voluntary recalls of its G7 and ONE/ONE+ iOS and watchOS apps worldwide due to a software defect that can delay or replay glucose readings and ...

For those in the diabetes community who’ve dreamed about seeing their in-the-moment blood sugar readings and trend data right on their smartwatch or bike computer while exercising, Dexcom and Garmin ...

In the lead-up to the American Diabetes Association’s Scientific Sessions, Dexcom announced an acquisition and Insulet rolled ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) and Companion Medical, Inc. today announced a collaboration to enable a direct exchange of CGM data from Dexcom with insulin data from InPen™ ...

Cardiometabolic digital diagnostics company Nanowear announced a licensing and data partnership with glucose monitoring specialist Dexcom to integrate glucose data from the Dexcom G7 into its ...

Dexcom, Inc., a leader in continuous glucose monitoring (CGM) for patients with diabetes, today announced the availability of enhanced data sharing features for physician and patient users of the ...

(Corrects to identify the issue is with the Dexcom Followmonitoring service, not the monitor itself) NEW YORK, Dec 1 (Reuters) - Dexcom Inc, which makescontinuous glucose monitoring systems that can ...